SGLT2 inhibitor therapy is associated with IL-10/TGF-α/sVEGFR3 signalling and adipose tissue remodelling in advanced heart failure. // Journal of Molecular and Cellular Cardiology Plus. – URL: https://www.sciencedirect.com/science/article/pii/S2772976126000279?dgcid=rss_sd_all
SGLT2 inhibitor therapy is associated with IL-10/TGF-α/sVEGFR3 signalling and adipose tissue remodelling in advanced heart failure. Journal of Molecular and Cellular Cardiology Plus. https://www.sciencedirect.com/science/article/pii/S2772976126000279?dgcid=rss_sd_all
“SGLT2 inhibitor therapy is associated with IL-10/TGF-α/sVEGFR3 signalling and adipose tissue remodelling in advanced heart failure.” Journal of Molecular and Cellular Cardiology Plus.
@article{article54391,
title = {SGLT2 inhibitor therapy is associated with IL-10/TGF-α/sVEGFR3 signalling and adipose tissue remodelling in advanced heart failure},
journal = {Journal of Molecular and Cellular Cardiology Plus},
url = {https://www.sciencedirect.com/science/article/pii/S2772976126000279?dgcid=rss_sd_all}
}